1. Home
  2. MREO

as 02-10-2025 11:39am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Founded: 2015 Country:
United Kingdom
United Kingdom
Employees: N/A City: LONDON
Market Cap: 482.5M IPO Year: N/A
Target Price: $7.83 AVG Volume (30 days): 1.3M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.31 EPS Growth: N/A
52 Week Low/High: $2.52 - $5.02 Next Earning Date: 03-26-2025
Revenue: $1,000,000 Revenue Growth: -88.89%
Revenue Growth (this year): -16.86% Revenue Growth (next year): 54.47%

MREO Daily Stock ML Predictions

Share on Social Networks: